Evolutionary Pressure against MHC Class II Binding Cancer Mutations

The anti-cancer immune response against mutated peptides of potential immunological relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8+ T cell responses. MHC-II-restricted CD4+ T cells also drive anti-tumor responses, but their relation to neoantigen selection and tumor evolution has not been systematically studied. Modeling the potential of an individual's MHC-II genotype to present 1,018 driver mutations in 5,942 tumors, we demonstrate that the MHC-II genotype constrains the mutational landscape during tumorigenesis in a manner complementary to MHC-I. Mutations poorly bound to MHC-II are positively selected during tumorigenesis, even more than mutations poorly bound to MHC-I. This emphasizes the importance of CD4+ T cells in anti-tumor immunity. In addition, we observed less inter-patient variation in mutation presentation for MHC-II than for MHC-I. These differences were reflected by age at diagnosis, which was correlated with presentation by MHC-I only. Collectively, our results emphasize the central role of MHC-II presentation in tumor evolution.

[1]  J. Voorberg,et al.  Analysis of the HLA‐DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation , 2017, Journal of leukocyte biology.

[2]  James Robinson,et al.  The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..

[3]  B. Bogen,et al.  How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? , 2014, Front. Immunol..

[4]  O. Lund,et al.  NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ , 2013, Immunogenetics.

[5]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[6]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[7]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[8]  R. Yamada,et al.  HLA‐HD: An accurate HLA typing algorithm for next‐generation sequencing data , 2017, Human mutation.

[9]  M. Nielsen,et al.  NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.

[10]  Angela Bachi,et al.  Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.

[11]  S. Wood.  Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models , 2011 .

[12]  PATHOGEN RESISTANCE AND GENETIC VARIATION AT MHC LOCI , 2002, Evolution; international journal of organic evolution.

[13]  Juan R. Cubillos-Ruiz,et al.  ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis , 2015, Cell.

[14]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[15]  Sebastian Bonhoeffer,et al.  Virus evolution: The importance of being erroneous , 2002, Nature.

[16]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[17]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[18]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[19]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[20]  H. Friess,et al.  Loss of heterozygosity in the HLA class I region in human pancreatic cancer. , 2004, Tissue antigens.

[21]  J. Yewdell,et al.  Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. , 2005, Annual review of immunology.

[22]  E. Kirkness,et al.  Fast and accurate HLA typing from short-read next-generation sequence data with xHLA , 2017, Proceedings of the National Academy of Sciences.

[23]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[24]  S. Elledge,et al.  Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.

[25]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[26]  Alessandro Vullo,et al.  Ensembl 2017 , 2016, Nucleic Acids Res..

[27]  Frank Noé,et al.  Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation , 2017, Front. Immunol..

[28]  T. Ideker,et al.  MHC-I Genotype Restricts the Oncogenic Mutational Landscape , 2017, Cell.

[29]  I. Messaoudi,et al.  Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense , 2002, Science.

[30]  M. Croft,et al.  Functional cooperation between T helper cell determinants. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[32]  M. Zanetti.  Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics , 2015, The Journal of Immunology.

[33]  Lincoln D. Stein,et al.  Quantifying immune-based counterselection of somatic mutations , 2017, bioRxiv.

[34]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[35]  Mark J. Smyth,et al.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.

[36]  Rong Wang,et al.  The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. , 2001, Trends in immunology.

[37]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[38]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[39]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[40]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[41]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[42]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[43]  Sean C. Bendall,et al.  Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.

[44]  Morten Nielsen,et al.  An automated benchmarking platform for MHC class II binding prediction methods , 2018, Bioinform..

[45]  M. Bevan,et al.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.

[46]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[47]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[48]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[49]  E. Unanue,et al.  Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. , 2016, Annual review of immunology.

[50]  J. Goedert,et al.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.

[51]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[52]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[53]  D. Cassell,et al.  Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes a , 1988, Annals of the New York Academy of Sciences.

[54]  N. Mitchison,et al.  The carrier effect in the secondary response to hapten‐protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis , 1971, European journal of immunology.

[55]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[56]  S. Xiong,et al.  Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus , 2003, European journal of immunology.

[57]  R. Zinkernagel,et al.  Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex , 1975, Nature.

[58]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[59]  E. Appella,et al.  Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. , 2000, Cancer research.

[60]  K. Willert,et al.  Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells , 2017, Science Signaling.

[61]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[62]  W. Thompson,et al.  Evolutionary Pressure against MHC Class II Binding Cancer Mutations , 2018, Cell.

[63]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[64]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[65]  Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. , 2015, Journal of immunological methods.

[66]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[67]  Trey Ideker,et al.  Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. , 2017, Cancer discovery.